Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based Cerulean Pharma, a developer of tumor-targeted nanopharmaceuticals, has dosed first non-small cell lung cancer (NSCLC) patients in a randomized Phase 2 trial of CRLX101.
Subscribe to our email newsletter
The trial aims to evaluate the safety and efficacy of CRLX101 in patients with advanced NSCLC whose disease has progressed following one or two prior regimens of therapy.
The company expects to recruit around 150 patients in the trial across 26 sites in Russia and Ukraine.
Cerulean chief medical officer Edward Garmey said based on exciting preclinical and clinical data, CRLX101 has the potential to be effective in both squamous and non-squamous histology patient populations, as well as in patients with a variety of tumor mutational markers including KRAS and EGFR.